MK-1406

COMBINATION_PRODUCT2 trials

Sponsors

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Merck Sharp & Dohme LLC

Conditions

HealthyInfluenza

Phase 1

A Clinical Trial of MK-1406 in Healthy Participants (MK-1406-008)

Not yet recruitingNCT07743151

Merck Sharp & Dohme LLCHealthy

Start: 2026-09-15End: 2027-02-05Target: 400Updated: 2026-08-03

Phase 3

A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)

Active, not recruitingNCT07159763

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Influenza

Start: 2025-09-25End: 2027-06-30Target: 10000Updated: 2026-09-17